01 Mar, 2022
Genor Biopharma announced today that GB242 (infliximab) has received approval from China’s National Medical Products Administration (NMPA) for the treatment of Rheumatoid Arthritis, Ankylosing Spondylitis, Psoriasis, Adult Ulcerative Colitis, Adult and Pediatric Crohn's Disease and Fistulising Crohn’s Disease.
Genor Biopharma included on the "2021 New Economy Most Valuable Listed Company" list by CaiLian Press
30 Dec, 2021
With the theme of "Gathering Momentum and Making a New Start", the “2021 New Economic Trends Lists” were officially released. Genor Biopharma was included on the "2021 New Economy Most Valuable Listed Company" list.
Genor Biopharma announces the appointment of several world-renowned experts to its Scientific Advisory Board
28 Dec, 2021
Genor Biopharma today announced the appointment of several world-renowned experts in tumor immunology & clinical oncology to its Scientific Advisory Board (SAB).
Genor Biopharma announces submission of clinical trial application for EGFR/cMET/cMET trispecific antibody (GB263T) in Australia
22 Dec, 2021
Genor Biopharma (Stock code: 6998.HK) announced today that the company has submitted a clinical trial application to the Bellberry HREC Ethics Committee in Australia on December 20 for the first-in-human (FIH) clinical trial of GB263T, a novel EGFR/cMET/cMET trispecific therapeutic antibody, in patients with advanced malignant tumors.
26 Nov, 2021
Shanghai Pudong New Area Intellectual Property Office issued the "Announcement of Special Funds for the Intellectual Property Operation Service System of Pudong New Area in 2021" to reward enterprises with an outstanding performance in intellectual property management capacity building. Genor Biopharma was one of the 12 outstanding enterprises in Shanghai’s Pudong New Area that received this award.